Agonist and antagonist effects of Cytisine (cas 15191-27-2) in vivo
-
Add time:07/31/2019 Source:sciencedirect.com
Varenicline, the most successful smoking cessation aid, is a selective partial agonists at α4β2* nicotinic receptors. Its efficacy is likely to be shared by other drugs with similar receptor action, including Cytisine (cas 15191-27-2). The present study aimed to characterize behavioral effects of cytisine compared with nicotine using locomotor activity tests, intracranial self-stimulation of ventral tegmental area (discrete-trial threshold current intensity titration procedure), drug discrimination (0.6 mg/kg nicotine from vehicle), physical dependence (osmotic minipumps delivering 6 mg/kg/day of nicotine) and intravenous nicotine self-administration (0.01 mg/kg per infusion) in adult Wistar rats. Cytisine (1–3 mg/kg) partially substituted for nicotine and at the highest dose tended to antagonize nicotine's discriminative stimulus effects. Nicotine (0.05–0.4 mg/kg), but not cytisine (0.3–3 mg/kg), lowered ICSS thresholds and cytisine dose-dependently reversed effects of nicotine. Nicotine (0.15–0.6 mg/kg), but not cytisine (0.3–3 mg/kg), stimulated locomotor activity and cytisine (3 mg/kg) fully reversed these effects of nicotine. Acute pretreatment with nicotine (0.15–0.6 mg/kg), but not cytisine (0.3–3 mg/kg), reinstated extinguished nicotine self-administration. Continuous infusion of nicotine induced physical dependence, as indicated by reduced rates of food-reinforced responding induced by a challenge dose of mecamylamine. At the highest tested dose (3 mg/kg), cytisine tended to reduce response rates irrespective of whether the rats were continuously exposed to nicotine or saline. Cytisine behaves like a weak partial agonist, mimicking effects of nicotine to a limited degree. Although cytisine reversed several effects of nicotine, it seemed to have a reduced potential to produce withdrawal signs in nicotine-dependent subjects.
We also recommend Trading Suppliers and Manufacturers of Cytisine (cas 15191-27-2). Pls Click Website Link as below: cas 15191-27-2 suppliers
Prev:Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine (cas 15191-27-2)
Next:Luminescent characterization of interaction efficiency between (−)-Cytisine (cas 15191-27-2) and amino acids an indicator of anti-inflammatory of some 12-N-substituted (−)-Cytisine (cas 15191-27-2) derivatives) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Synthesis and evaluation of camphor and Cytisine (cas 15191-27-2)-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus08/04/2019
- Cytisine (cas 15191-27-2) basicity, solvation, log P, and log D theoretical determination as tool for bioavailability prediction08/03/2019
- Designing and preparation of Cytisine (cas 15191-27-2) alkaloid surface-imprinted material and its molecular recognition characteristics08/02/2019
- Luminescent characterization of interaction efficiency between (−)-Cytisine (cas 15191-27-2) and amino acids an indicator of anti-inflammatory of some 12-N-substituted (−)-Cytisine (cas 15191-27-2) derivatives08/01/2019
- Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine (cas 15191-27-2)07/30/2019
- Novel Cytisine (cas 15191-27-2) derivatives exert anti-liver fibrosis effect via PI3K/Akt/Smad pathway07/29/2019
- Efficient synthesis of tetrazole derivatives of Cytisine (cas 15191-27-2) using the azido-Ugi reaction07/28/2019
- Spectral and photophysical properties of Cytisine (cas 15191-27-2) in acetonitrile – Theory and experiment07/27/2019